---
schema_version: "secwatch.filing_event.v1"
accession: "0001837607-25-000065"
form_type: "8-K"
ticker: "AEON"
cik: "0001837607"
company_name: "AEON Biopharma, Inc."
filed_at: "2025-08-12T23:59:59+00:00"
generated_at: "2026-05-17T14:50:14.225998+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "medium"
source: SEC EDGAR
---

# AEON Biopharma reports Q2 2025 cash of $8.4M; advancing ABP-450 biosimilar milestones

## Summary
- Cash and equivalents $8.4M as of June 30, 2025; expected to fund operations through Q4 2025 and Type 2a FDA meeting.
- Primary structure and select functional analyses for ABP-450 expected to complete in Q3 2025.
- Type 2a meeting with FDA on 351(k) biosimilar pathway anticipated in Q4 2025.
- Pursuing ABP-450 as BOTOX biosimilar for all therapeutic indications; over $3B U.S. therapeutic market opportunity noted.

## SEC filing metadata
- accession: 0001837607-25-000065
- form_type: 8-K
- ticker: AEON
- cik: 0001837607
- company_name: AEON Biopharma, Inc.
- filed_at: 2025-08-12T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: medium
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1837607/000183760725000065/0001837607-25-000065-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1837607/000183760725000065/aeon-20250812x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001837607-25-000065
- JSON: https://secwatch.observer/filing/0001837607-25-000065.json
- Plain text: https://secwatch.observer/filing/0001837607-25-000065.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.